3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
7
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
3082
Neoplasms, Plasma Cell
614
Lymphoma
455
Lymphoma, Non-Hodgkin
428
Recurrence
371
Hodgkin Disease
366
Leukemia, Lymphocytic, Chronic, B-Cell
362
Precursor Cell Lymphoblastic Leukemia-Lymphoma
340
Leukemia, Myeloid, Acute
322
Leukemia
321
Myelodysplastic Syndromes
287
Lymphoma, Mantle-Cell
262
Lymphoma, Large B-Cell, Diffuse
259
Lymphoma, Follicular
254
Lymphoma, B-Cell, Marginal Zone
231
Burkitt Lymphoma
227
Lymphoma, Large-Cell, Immunoblastic
203
Myeloproliferative Disorders
197
Immunoglobulin Light-chain Amyloidosis
184
Neoplasms
182
Hematologic Neoplasms
169
Primary Myelofibrosis
167
Leukemia, Myeloid, Chronic-Phase
165
Leukemia, Myeloid, Accelerated Phase
154
Lymphoma, T-Cell, Cutaneous
150
Waldenstrom Macroglobulinemia
145
Blast Crisis
143
Leukemia, Myelomonocytic, Chronic
140
Mycosis Fungoides
129
Sezary Syndrome
128
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Amyloid Neuropathies, Familial
×
Plasma cell
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled